Latest Deals

Credit: Shutterstock/Dragana Gordic

Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease

Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) primarily focusing on coeliac disease. Takeda will secure exclusive worldwide rights to use a set of Innate antibodies to create, manufacture and commercialise the ADCs. In addition to milestone-based payments, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.

Source: Pharmaceutical Technology

India’s Cipla signs licence deal with Novartis for diabetes drug Galvus

India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands.  Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026. Galvus brand products are mainly used in the treatment of patients with type 2 diabetes.

Source: Pharmaceutical Technology

GSK signs licence deal with Scynexis for fungal infection treatment

GSK has signed an exclusive licence agreement with Scynexis to commercialise and further develop Brexafemme (ibrexafungerp tablets) to treat fungal infection. GSK will obtain the rights to commercialise the new oral glucan synthase inhibitor for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC).

Source: Pharmaceutical Technology

BioNTech and DualityBio team up to develop ADC therapeutics for cancer

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. As part of the new deals, BioNTech will have commercial rights to the ADCs worldwide, excluding mainland China, the Hong Kong special administrative region and the Macau special administrative region.

Source: Pharmaceutical Technology

Go to article: Home | Nanoparticle drug delivery research gets a boostGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: NiproGo to article: In DepthGo to article: Covid-19 vaccine success bolsters nanoparticle drug delivery research Go to article: eConsent in clinical trials: What’s on the horizon?Go to article: Breathing easy: How digital inhalers are changing asthma treatmentGo to article: Primate models in pharma: What the future holds Go to article: A decade on, what’s next for CAR-T therapies?Go to article: FDA’s $7bn plan for 2024: Disclose CMOs, restart Cancer MoonshotGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: ForewordGo to article: ESG is the most important theme of this decadeGo to article: A timeline of corporate ESGGo to article: The most pressing ESG concerns for the pharma industryGo to article: Key trends impacting ESG performance in the healthcare sectorGo to article: Latest news: ESG in pharmaGo to article: Sustainable supply chains: Clinical trials in a new era of limited resourcesGo to article: Increase in DPI use could lead to decreases in greenhouse gas emissionsGo to article: Environmental sustainability innovation: Leading companies in anti-malarial compositionsGo to article: Deal activity related to ESG in the pharmaceutical industry since 2020Go to article: ESG hiring trends in the global pharmaceutical industry since 2020Go to article: ESG patent applications in the global pharmaceutical industry since 2020Go to article: Mentions of ESG in pharmaceutical industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Pharma Sponsored SupplementsGo to article: CfPIEGo to article: ListingsGo to article: EventsGo to article: RankingsGo to article: Buyer's GuidesGo to article: Next issue